

Evolution and spread of multi-adapted pathogens in a spatially heterogeneous environment

Quentin Griette¹, Matthieu Alfaro², Gaël Raoul^{3*}, and Sylvain Gandon^{4*@}

¹Normandie Univ, UNIHAVRE, LMAH, FR-CNRS-3335, ISCN, Le Havre 76600, France.

²Univ. Rouen Normandie, CNRS, LMRS UMR 6085, F-76000 Rouen, France.

³CMAP, CNRS, Ecole polytechnique, I.P. Paris, 91128 Palaiseau, France.

⁴CEFE, CNRS, Univ Montpellier, EPHE, IRD, Montpellier, France.

*Contributed equally

December 12, 2022

Abstract

The emergence and the spread of multi-adapted pathogens is often viewed as a slow process resulting from the incremental accumulation of single adaptations. In bacteria, for instance, multidrug resistance to antibiotics may result from the sequential acquisition of single drug resistance to different antibiotics. In phytopathogens, the ability to infect different resistant varieties of crops may also result from the accumulation of distinct virulence genes. Here we use a general epidemiological model to analyse the evolution of pathogen adaptations throughout an epidemic spreading in a heterogeneous host population where selection varies periodically in space. This spatially heterogeneous selection may result from the use of different drugs, different vaccines or different crop varieties in agriculture. We study both the transient evolution of pathogen adaptation at the front of the epidemic and the long-term evolution far behind the epidemic front. We identify five different types of epidemic profiles that may arise from different combinations of spatial heterogeneity and the cost of multi-adaptation. In particular, we show that multi-adaptation can drive epidemic spread, while the evolution of single-adaptation may only occur in a second phase, when the pathogen specializes on local selective pressures. Indeed, a generalist pathogen with multiple adaptations can outpace the spread of a coalition of specialist pathogens when selection varies frequently in space. This result is amplified in finite host populations because demographic stochasticity can lead to the extinction of maladapted pathogens specialised to a local selective pressure. Our work has important implications for the management of multiple drugs and vaccines against pathogens but also for the optimal deployment of resistant varieties in agriculture.

Keywords: multiresistance, drugs, spatial heterogeneity, epidemic spread

1 Introduction

The rise of antimicrobial resistance is a major public-health issue [1]. In particular, the emergence and the spread of bacteria carrying resistance to multiple antibiotics erode our ability to cure these infections [2, 3]. The evolution of multiresistant pathogens is often viewed as the result of the slow accumulation of resistance genes after the persistent use of different drugs in the host population. Similarly, pathogen adaptation to different vaccines or to different resistant varieties of crops may involve the sequential acquisition of distinct escape mutations. Under this scenario, the evolution of a broader range of resistance to drugs (i.e., multi-adaptation) is viewed as an unavoidable long term consequence of the use of multiple drugs. However, the long-term coexistence of bacteria that differ in the range of drug resistance (i.e., single-adaptation) challenges this view [4, 5]. Several theoretical studies highlighted the importance of different forms of heterogeneities in the structure of the host population to maintain the coexistence between sensitive and resistant bacteria [6, 7, 8, 9, 10, 11]. For instance, spatial variation in drug treatment can readily maintain this long-term coexistence when migration is limited among host populations [6, 7, 9]. Spatial variation in selection may also emerge in spatially spreading epidemics where selection acting at the frontline of the epidemic may differ from selection behind the front [12, 13, 14]. These earlier studies focused on the evolution of pathogen life-history traits like virulence and transmission in epidemics spreading in a homogeneous environment. Here we explore the interplay between pathogen epidemiology and the evolution of drug resistance in a spatially heterogeneous environment.

The spread of epidemics in homogeneous environments can be described by a *travelling front* where the pathogen propagates through space at a constant speed [13, 14, 15]. In a spatially heterogeneous environment, the variation of the quality of the habitat affects the speed of epidemic spread. Yet, if the spatial variation is periodic, the natural extension of the travelling front is the so-called *pulsating front* characterized by its average speed [15, 16, 17]. In the following we take advantage of the theoretical framework of pulsating fronts to examine the spatial dynamics of different pathogens spreading in a one-dimensional environment. We further assume that the host is constantly exposed to a single selective pressure (e.g., an antibiotic) but the type of selection (e.g., the identity of the drug) varies periodically in space. In a second step, we allow mutations between different pathogen genotypes and we analyse the evolution of a coalition of different pathogen genotypes. Finally, we examine the effect of demographic stochasticity on the speed of spreading epidemics when host population are assumed to be finite.

2 Model

We model the dynamics of a directly transmitted pathogen in a one-dimensional habitat. At time t and position x , the host population is divided into uninfected individuals, $S(t, x)$, and infected individuals, $I(t, x)$. We assume that dead hosts are immediately replaced by new susceptible hosts so that the total density of hosts is assumed to remain constant over space and time: $K = S(t, x) + I(t, x)$. We focus on a scenario where the environment is divided into two different habitats where all the hosts are treated by either drug A or drug B . But the two types of hosts could also be due to the use of two different vaccines or, if we consider the spread of a phytopathogen in crop, by the use of two resistant varieties in different fields. We consider a simple spatial pattern where treatment varies periodically and we use L to denote the period of the spatial fluctuation of the treatment. Because all the hosts are treated by a drug we expect that the pathogens sensitive to both drugs will be rapidly outcompeted by resistant genotypes. We thus focus our analysis on the dynamics of three resistant pathogen genotypes circulating in the host population: (i) the density of hosts infected with the genotype only resistant to drug A is noted $I_a(t, x)$, (ii) the density of hosts infected with the genotype only resistant to drug B is noted $I_b(t, x)$ and (iii) the density of hosts infected with the genotype resistant to both drugs is noted $I_m(t, x)$ (m for multiresistance). Coinfection by different genotypes is not allowed and each genotype i is characterized by $\beta_i(x)$, the rate at which transmission occurs between infected and susceptible

80 hosts after a contact at position x . The rate of transmission of the multiresistant genotype β_m is
 81 independent of space because multiresistance implies that the rate of transmission is not affected by
 82 the treatment. In contrast, the rates of transmission $\beta_a(x)$ and $\beta_b(x)$ vary in space because we assume
 83 that treatment reduces transmission (without affecting the other life history traits). All the infections
 84 are assumed to end (because of clearance and/or increased mortality due to pathogen virulence) at
 85 a rate α . More precisely, we assume that β_a (resp. β_b) takes values $\alpha + r$ in locations treated by
 86 drug A only (resp. B only), and value $\alpha - r$ in locations treated by drug B only (resp. A only), see
 87 **Fig. 1**. This symmetry between the two specialists simplifies the following analysis of the model.
 88 Note, however, that we also examine a scenario when we introduce some asymmetry in the maximal
 89 growth rates of the two specialists in the **Supplementary Information** (section 1.2.1). Mutations
 90 may occur between these three genotypes and μ_{ij} stands for the rate of mutation from genotype i to
 91 genotype j .

92 The transmission of the pathogen is assumed to be local (infected hosts can only infect susceptible
 93 hosts at the same spatial location) but both susceptible and infected hosts are allowed to diffuse in
 94 one dimension with a fixed rate σ . In other words, we neglect the influence the pathogen may have
 95 on the mobility of its host. Our model can thus be written as the following set of reaction–diffusion
 96 equations (for readability, we drop the time and space dependence notation on host densities):

$$\begin{cases} \frac{\partial I_a}{\partial t} = I_a \left[r_a(x) - \beta_a(x) \frac{I}{K} \right] + \sigma \frac{\partial^2 I_a}{\partial x^2} + \mu_{ba} I_b + \mu_{ma} I_m - (\mu_{ab} + \mu_{am}) I_a \\ \frac{\partial I_b}{\partial t} = I_b \left[r_b(x) - \beta_b(x) \frac{I}{K} \right] + \sigma \frac{\partial^2 I_b}{\partial x^2} + \mu_{ab} I_a + \mu_{mb} I_m - (\mu_{ba} + \mu_{bm}) I_b \\ \frac{\partial I_m}{\partial t} = I_m \left[r_m - \beta_m \frac{I}{K} \right] + \sigma \frac{\partial^2 I_m}{\partial x^2} + \mu_{am} I_a + \mu_{bm} I_b - (\mu_{ma} + \mu_{mb}) I_m \end{cases} \quad (1)$$

97 where $I = I_a + I_b + I_m$ and $r_i(x) = \beta_i(x) - \alpha$ is the malthusian growth rate of the single-resistance
 98 genotype i (with $i \in \{a, b\}$). Similarly, $r_m = \beta_m - \alpha$ is the malthusian growth rate of the multiresistant
 99 genotype m .

100 In the following we study the speed of spreading epidemics in a spatially heterogeneous environment
 101 as a function of (i) the period of the spatial fluctuation in drug use, (ii) the transmission rates of
 102 the different genotypes in the different habitats. We first consider the spread of single genotypes
 103 before analysing the effect of mutations among genotypes on the speed of a polymorphic pathogen
 104 population. Finally, we explore the effect of demographic stochasticity on the speed of monomorphic
 105 and polymorphic epidemics spreading in heterogeneous environments.

106 3 Results

107 3.1 The speed of a monomorphic pathogen population

108 The multiresistant genotype does not “feel” the spatial heterogeneity of the drug treatment. When
 109 such a genotype is introduced in the host population and if we assume no mutation ($\mu_{ma} = \mu_{mb} = 0$)
 110 the above system reduces to the spread of a single pathogen in a uniform environment. The pathogen
 111 population spreads as a traveling wave with a speed equal to [13, 14, 15]:

$$c_m = 2\sqrt{\sigma r_m}. \quad (2)$$

112 The analysis of the speed of a single-resistance genotype $i \in \{a, b\}$ is more challenging because the
 113 growth rate of the pathogen varies periodically in space between $r_i(x) = r$ (when the genotype is
 114 resistant to the drug applied in x) and $r_i(x) = -r$ (when the genotype is not resistant to the drug
 115 applied in x). It is possible to derive good approximations for the speed of the epidemic in two limit
 116 cases [18, 19], namely when L is small and when L is large. When the period of the fluctuation of the
 117 environment is very small (i.e. $L \rightarrow 0$) the *grain* of the environment is so small that the growth rate

118 of the pathogen is equal to the average growth rate in the two habitats: $\bar{r} = \frac{r+(-r)}{2} = 0$. In contrast,
 119 when the period of the fluctuation is large the pathogen will move very fast when it is resistant to
 120 drug and it will slow down when the drug reduces its transmission rate. In the limit when $L \rightarrow \infty$ the
 121 speed reaches an asymptote that can be described explicitly. We then get, for $i \in \{a, b\}$,

$$c_i \sim 0 \text{ when } 0 < L \ll 1, \quad c_i \sim \left(\frac{2}{\sqrt{3}}\right)^{3/2} \sqrt{r} \text{ when } 1 \ll L. \quad (3)$$

122 Moreover the speed of the single-resistance genotype epidemic increases with L , the period of the
 123 spatial fluctuation of the environment (**Fig. 2**).

124 3.2 The speed of a polymorphic pathogen population

125 Before considering the full system (with the 3 resistant genotypes) we examine the dynamics of a
 126 coalition of two single-resistance genotypes that resist two different drugs. When the mutation rates
 127 are very low (i.e. $\mu_{aj} = \mu_{bj} \approx 0$) we recover the result of a monomorphic population (red line in
 128 **Fig. 2**). However, numerical simulations with a fixed mutation rate μ between single-resistant geno-
 129 types indicate that increasing the mutation rate has a complex effect on the speed of the polymorphic
 130 population (**Fig. 2**). When L is small, increasing the mutation rate has only a weak effect on epidemic
 131 speed because the environment changes so fast that both resistant genotypes are almost equiprevalent.
 132 For intermediate values of L , the size of the area treated homogeneously with a single drug allows
 133 the resistant genotype to outcompete the other genotype and to take up some speed. Hence, the
 134 composition of the epidemic fluctuates between the two specialist genotypes and a higher mutation
 135 rate speeds up the emergence of this locally adapted genotype and increases the propagation speed.
 136 For larger values of L , however, this effect is dominated by the detrimental emergence of ill-adapted
 137 mutants (*mutation load*) that slows down the propagation within an area treated by a single drug.
 138 Hence, the composition of the pathogen population at the front of the epidemic depends on the balance
 139 between local selection, mutation and L which measures the amount of spatial heterogeneity. We show
 140 in the **Supplementary Information** (section 1.2.1) that there is a threshold value L_c below which
 141 the whole epidemic can be driven by a single specialist:

$$L_c \sim \frac{2\sqrt{2}}{3^{3/4} - \sqrt{2}} \sqrt{\frac{\sigma}{r}} \ln \left(\frac{\sqrt{\sigma r}}{\mu} \right). \quad (4)$$

142 When $L < L_c$ the propagation of each specialist is independent because they can move through the
 143 “bad habitat” by diffusion. In contrast, when $L > L_c$ the bad habitat slows down the spread of the
 144 maladapted specialist and the coalition of two specialists is faster than a single specialist because they
 145 “pass the baton” when they move to a different habitat. The composition of the pathogen population
 146 at the front of the epidemic fluctuates between the two specialist genotypes. Higher mutation rates
 147 speed up the epidemic because mutation speeds up the switch between the two specialists at the tip
 148 of the front. Note, however, that high mutation rates generate a *mutation load* when $L \gg L_c$ via
 149 the recurrent introduction of a drug sensitive genotype in the pathogen population. This is why the
 150 maximal speed of the coalition of single-resistance genotypes can never reach the speed of a universally
 151 adapted pathogen ($c_{a+b} < 2\sqrt{\sigma r}$ in **Fig. 2**).

152 When we assume a fixed mutation rate μ among the three resistant genotypes, the epidemic spreads
 153 faster than epidemics where only the coalition of two specialists is present, provided the period of the
 154 fluctuation is small (**Fig. 3**). Indeed, when L is small the multiresistant genotype outpaces the
 155 single-resistant genotypes at the front of the epidemic (**Fig. 3**). In contrast, when L is large, the
 156 multiresistant genotype is outcompeted by the coalition of the two specialists (in particular when
 157 the mutation rate between single-resistant genotypes is large enough). Increasing the mutation rate
 158 tends to lower the speed of the epidemic when L is small or very large, because mutations reintroduce
 159 maladapted genotypes and build up the mutation load (**Fig. 4**). For intermediate values of L ,
 160 however, increasing the mutation rate can increase the speed of the pathogen spread, by speeding up

161 the propagation of a the coalition of specialists a and b (**Fig. 4**). This is due to the beneficial effects
162 of mutations on the speed of the coalition of two single-resistant genotypes that we discussed above
163 (**Fig. 2**).

164 3.3 The speed of stochastic epidemics

165 The above results rely on the assumption that the deterministic model we are using provides a good
166 description of the spread of a pathogen epidemics. Yet, the front of the epidemic is necessarily driven
167 by a small number of infections. The finite nature of the pathogen population at the edge of the
168 epidemics yields demographic stochasticity and is expected to slow down its spread [14, 20, 21, 22].
169 In the following we explore the effect of stochasticity using an individual-based model that takes into
170 account the finite number N of hosts at each spatial location. The individual transitions between the
171 different states of the hosts are described by a list of random events (transmission, mutation, death; see
172 the **Supplementary Information** for a detailed description of the individual-based model, section
173 2). As expected, this stochastic model converges to the above deterministic model when N is assumed
174 to be very large. To study the effect of demographic stochasticity on epidemic spread we performed
175 simulations with our individual-based model and measured the average speed on a long time interval
176 after the influence of the initial condition is lost.

177 First, we discuss the speed of monomorphic epidemics in the absence of mutations. The speed of
178 the multiresistant genotype is decreased by the effect of stochasticity but remains very close to the
179 deterministic approximation (see [14, 20]). The magnitude of this drop is expected to be proportional
180 to $(\ln(\frac{N}{\delta x}))^{-2}$, where $\frac{N}{\delta x}$ represents the number of hosts per unit of space. In contrast, the speed
181 of the single-resistant mutant is dramatically altered by stochasticity (**Fig. 3**). This speed is always
182 lower than the speed of the deterministic approximation but, when L is large the speed can drop
183 abruptly to zero which indicates that the pathogen cannot spread any more. Indeed, when the period
184 of the fluctuation of the environment reaches a threshold value $L_e \sim \frac{4}{3} \sqrt{\frac{\sigma}{r}} \ln(\frac{N}{\delta x})$ the pathogen cannot
185 cross the unfavourable habitat (see **Supplementary Information**, section 2.2.2). In particular, the
186 pathogen is very likely to go extinct in the unfavourable habitat when the population size is small, the
187 diffusion rate is limited and its growth rate is very negative (remember that we assume the growth rate
188 to be $-r$ in the unfavourable habitat). Note that this critical period L_e only increases logarithmically
189 with the population size N , so that this blocking effect can be observed even with relatively large
190 population sizes. This explains why the propagation speed of a single-resistance genotype is maximised
191 for intermediate values of L . In the deterministic approximation, in contrast, the pathogen can always
192 cross unfavourable habitats because extinctions do not occur and the speed of epidemic spread increases
193 monotonically with L .

194 Second, if we allow some mutation between the two single-resistant genotypes, the epidemic can
195 cross those unfavorable environments because mutations will rescue pathogen populations when $L >$
196 L_e . Consequently, increasing mutation rates can have a dramatic impact on the speed of epidemics
197 when L is large (**Fig. 4**). Finally, when we allow the mutation between the three different genotypes,
198 the speed of the epidemics is close to (but lower) than the deterministic approximation, and this speed
199 can decrease when $L > L_e$ and the mutation rates are small enough (**Fig. 4**). As pointed out above,
200 the magnitude of this effect on the reduction of the epidemic speed is of the order $(\ln(N))^{-2}$ when N
201 is large enough.

202 3.4 Pathogen diversity far behind the epidemic front

203 In the previous sections we focused on the composition of the pathogen population at the edge of the
204 epidemic. Next, we characterise the composition of the pathogen population far behind the front, when
205 it reaches an endemic equilibrium. Note that the composition of the pathogen population behind the
206 front is much less sensitive to the effect of demographic stochasticity because at the endemic equilibrium,
207 the number of pathogen present is much larger than at the front of the epidemics, diminishing greatly
208 the risk of genotype extinctions. Hence, we do not need to distinguish the deterministic and stochastic

209 models in this section. Three cases can be observed (**Fig. 5**):

210 **(i) The multiresistant genotype dominates:** If both the cost of being multiresistant (i.e. $r - r_m$)
211 and L are low, the generalist strategy outcompetes the specialists and goes to fixation.

212 **(ii) The coalition of specialist genotypes dominates:** When both the cost of being multiresistant
213 (i.e. $r - r_m$) and L are large, the coalition of specialists outcompetes the generalist strategy.

214 **(iii) The three genotypes coexist:** The coexistence between the three different genotypes is also
215 possible for a range of parameter values when both r_m and L are relatively large. As pointed by [23],
216 a generalist strategy can outcompete specialits at the interface between habitats.

217 3.5 Five epidemic profiles

218 Combining the different modes of propagation and the different types of pathogen populations behind
219 the front, we can distinguish five different profiles of epidemics (**Fig. 5**). Interestingly, we identify
220 an epidemic type (marked by **III** in **Fig. 5**, see also **Fig. 6**) where the multiresistant genotype m
221 drives the spread of the epidemic but is outcompeted later on by the coalition of the two specialists
222 (single-resistance genotypes a and b). In other words, the analysis of the transitory dynamics reveals
223 conditions where the multiresistant genotype is able to emerge, taking advantage of the presence of
224 numerous uninfected host populations, even though specialized strategies are better competitors once
225 the epidemics has developed and many hosts have been infected.

226 We recover the same five epidemic profiles with finite host population sizes (**Fig. 5**) but demo-
227 graphic stochasticity affects the genetic diversity at the front of the epidemic where the size of the
228 pathogen population is reduced. Single-resistance genotypes are most sensitive to the influence of
229 stochasticity because these specialized genotypes can reach very low density in unfavourable habitats.
230 The multiresistant genotype m benefits from the influence of this demographic stochasticity (compare
231 the size of epidemic type marked by **III** in the deterministic and stochastic cases illustrated by **Fig. 5**).

232 4 Discussion

233 Adaptation to a diverse range of selective pressures (e.g., drugs, specific immune responses, different
234 host genotypes) is expected to result in the accumulation of multiple adaptations (drug resistance,
235 immune escape mutations, virulence alleles) in pathogen populations. Ultimately, this process may
236 lead to the emergence of multi-adapted (i.e. multiresistant) pathogens and a dramatic erosion of the
237 efficacy of control measures. This major public-health concern requires a better understanding of
238 the spatial spread of pathogen adaptations and our analysis challenges the view that the evolution
239 of multiresistance is an unavoidable consequence of the use of multiple drugs against pathogens. We
240 show that multiresistant pathogens can drive the spread of pathogen epidemics in spatially variable
241 environments. Indeed, a multiresistant genotype is a *generalist* strategy that better copes with the
242 heterogeneity of the environment during the early stage of a spreading epidemic. In the long term,
243 however, the single-resistance genotypes are *specialist* strategies that are locally adapted to single drug
244 treatments. Consequently, spreading epidemics may start with a multiresistant pathogen and end with
245 a coalition of single-resistant genotypes (**Fig. 6**).

246 Earlier studies have either looked at the evolution of polymorphic pathogen populations spreading
247 in homogeneous environments [12, 13, 14] or at monomorphic populations spreading in heterogeneous
248 environments [15, 16, 17]. The originality of our work relies on the analysis of the speed of a polymor-
249 phic population in a heterogeneous environment. We show that mutation is a double edged sword: (i)
250 it allows the pathogen to acquire new resistance mutations and thus to adapt to new drugs but (ii) it
251 can also produce a mutation load with the recurrent introduction of poorly adapted genotypes. The
252 balance between these two effects depends on the heterogeneity of the environment which, in turn,
253 depends on the ratio between the period L of the fluctuation of the environment and the diffusion
254 coefficient σ . The beneficial effect of a higher mutation rate is maximal for intermediate levels of this
255 ratio. Indeed, it is not profitable for the pathogen population to mutate often when the environment

256 keeps changing (i.e., $L \sim 0$) or when the environment changes very slowly (i.e., $L \rightarrow \infty$). Several earlier
257 studies obtained similar conclusions in non-spatial models where it is possible to show that there is an
258 optimal stochastic switching rate between specialized phenotypes that maximizes the growth rate of
259 a population in a fluctuating environment [24, 25]. In all these different scenarios, the introduction of
260 genetic variation provides a way to “pass the baton” between different specialist genotypes and allows
261 the population to exploit more efficiently a fluctuating environment.

262 As expected from earlier theoretical studies [14, 20, 21, 22], demographic stochasticity lowers the
263 speed of the epidemic spread. Most of the results of the deterministic model hold in finite host
264 populations. The only notable exception occurs when large values of L can prevent the spread of
265 single-resistance genotypes. The input of new mutations, however, may provide a way to adapt to the
266 new drug. Hence the speed of pathogen epidemics may be constrained by both the stochastic nature
267 of the demographic process and the stochastic nature of the mutation events occurring at the edge of
268 the epidemic.

269 Several experimental studies have monitored and quantified the spread and the evolution of a
270 bacteria in laboratory conditions [26, 27]. In particular, the MEGA-plate experiment of Baym et
271 al followed the spread of *Escherichia coli* in a spatially heterogeneous environment characterised by
272 increasing concentrations of antibiotics. This fascinating experiment allowed to visualize pathogen
273 spread and evolution in real time. This experimental procedure could be used to test some of our
274 predictions. For instance, we could monitor the influence of the scale of spatial heterogeneity with a
275 manipulation of the parameter L in the MEGA-plate. We hope that the present theoretical framework
276 may stimulate an experimental validation of our theoretical predictions using experimental evolution
277 of microbes in spatially heterogeneous environments.

278 Our models can be used to make very practical recommendations regarding the manipulation of
279 the spatial structure of the environment. This spatial structure can be manipulated by the spatially
280 heterogeneous use of therapeutic drugs to treat infections [6, 28, 29] but also the deployment of
281 resistance genes against pathogens in plants [7, 30, 31, 32, 33]. If the objective is to limit the speed of
282 the epidemic spread, a lower value of L should be recommended. Lower L values imply that a spreading
283 epidemics is exposed to a more variable environment. This prevents the pathogen to specialize to
284 a specific environment and, consequently, to speed up in a favourable environment. Interestingly,
285 fine-scale environmental heterogeneity (low L values) are also expected to reduce the probability of
286 pathogen emergence [34]. This fine-scale heterogeneity, however, may promote the spread of generalist
287 and multiresistant pathogens. Those pathogens are likely to spread more slowly because of the fitness
288 cost associated with multiple resistance genes. Avoiding the spread of pandrug-resistance which erodes
289 the efficacy of therapeutic drugs may be viewed as a public-health priority. Besides, after the spread
290 of multiresistant genotypes, additional compensatory mutations (not considered in our model) may
291 restore the competitiveness of those genotypes against single-resistance genotypes. Those compensatory
292 mutations could promote the persistence of pandrug-resistance in the long-term. In other words, the
293 optimal deployment of control measures in space varies with the forecast horizon. Our model helps
294 clarify the consequences of these interventions on the short term epidemiological dynamics (the speed
295 of the spreading epidemic) as well as the evolutionary dynamics of the pathogen population.

296 5 Acknowledgements

297 We thank the CNRS MITI for funding the project VIRADAPT&SPREAD.

298 References

- 299 [1] World Health Organization et al. *Antimicrobial resistance and primary health care: brief*. Tech.
300 rep. World Health Organization, 2018.

- 301 [2] Alison H Holmes et al. “Understanding the mechanisms and drivers of antimicrobial resistance”.
302 In: *The Lancet* 387.10014 (2016), pp. 176–187.
- 303 [3] Alessandro Cassini et al. “Attributable deaths and disability-adjusted life-years caused by infec-
304 tions with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a
305 population-level modelling analysis”. In: *The Lancet infectious diseases* 19.1 (2019), pp. 56–66.
- 306 [4] European Centre for Disease Prevention and Control. “European Centre for Disease Prevention
307 and Control. Antimicrobial resistance surveillance in Europe 2015”. In: *Annual Report of the Eu-
308 ropean Antimicrobial Resistance Surveillance Network (EARS-Net)*. Stockholm: ECDC (2017).
- 309 [5] Herman Goossens et al. “Outpatient antibiotic use in Europe and association with resistance: a
310 cross-national database study”. In: *The Lancet* 365.9459 (2005), pp. 579–587.
- 311 [6] Florence Débarre, Sebastian Bonhoeffer, and Roland R Regoes. “The effect of population struc-
312 ture on the emergence of drug resistance during influenza pandemics”. In: *Journal of The Royal
313 Society Interface* 4.16 (2007), pp. 893–906. DOI: 10.1098/rsif.2007.1126.
- 314 [7] Andrew W. Park et al. “Refugia and the evolutionary epidemiology of drug resistance”. In:
315 *Biology Letters* 11.11 (2015), p. 20150783. DOI: 10.1098/rsbl.2015.0783.
- 316 [8] Sonja Lehtinen et al. “Evolution of antibiotic resistance is linked to any genetic mechanism
317 affecting bacterial duration of carriage”. In: *Proceedings of the National Academy of Sciences*
318 114.5 (2017), pp. 1075–1080.
- 319 [9] François Blanquart et al. “The evolution of antibiotic resistance in a structured host population”.
320 In: *Journal of The Royal Society Interface* 15.143 (2018), p. 20180040.
- 321 [10] François Blanquart. “Evolutionary epidemiology models to predict the dynamics of antibiotic
322 resistance”. In: *Evolutionary applications* 12.3 (2019), pp. 365–383.
- 323 [11] Sonja Lehtinen et al. “On the evolutionary ecology of multidrug resistance in bacteria”. In: *PLoS
324 pathogens* 15.5 (2019), e1007763.
- 325 [12] Wei Wei and Stephen M Krone. “Spatial invasion by a mutant pathogen”. In: *Journal of theo-
326 retical biology* 236.3 (2005), pp. 335–348.
- 327 [13] Erik E Osnas, Paul J Hurtado, and Andrew P Dobson. “Evolution of pathogen virulence across
328 space during an epidemic”. In: *The American Naturalist* 185.3 (2015), pp. 332–342.
- 329 [14] Quentin Griette, Gaël Raoul, and Sylvain Gandon. “Virulence evolution at the front line of
330 spreading epidemics”. In: *Evolution* 69.11 (2015), pp. 2810–2819.
- 331 [15] Nanako Shigesada and Kohkichi Kawasaki. *Biological invasions: theory and practice*. Oxford
332 University Press, UK, 1997.
- 333 [16] Henri Berestycki, François Hamel, and Lionel Roques. “Analysis of the periodically fragmented
334 environment model. I. Species persistence”. In: *J. Math. Biol.* 51.1 (2005), pp. 75–113. ISSN:
335 0303-6812. DOI: 10.1007/s00285-004-0313-3.
- 336 [17] Henri Berestycki, François Hamel, and Lionel Roques. “Analysis of the periodically fragmented
337 environment model. II. Biological invasions and pulsating travelling fronts”. In: *J. Math. Pures
338 Appl. (9)* 84.8 (2005), pp. 1101–1146. ISSN: 0021-7824. DOI: 10.1016/j.matpur.2004.10.006.
- 339 [18] François Hamel, Julien Fayard, and Lionel Roques. “Spreading speeds in slowly oscillating en-
340 vironments”. In: *Bull. Math. Biol.* 72.5 (2010), pp. 1166–1191. ISSN: 0092-8240. DOI: 10.1007/
341 s11538-009-9486-7.
- 342 [19] François Hamel, Grégoire Nadin, and Lionel Roques. “A viscosity solution method for the spread-
343 ing speed formula in slowly varying media”. In: *Indiana Univ. Math. J.* 60.4 (2011), pp. 1229–
344 1247. ISSN: 0022-2518. DOI: 10.1512/iumj.2011.60.4370.
- 345 [20] Eric Brunet and Bernard Derrida. “Shift in the velocity of a front due to a cutoff”. In: *Physical
346 Review E* 56.3 (1997), p. 2597.

- 347 [21] Robin E Snyder. “How demographic stochasticity can slow biological invasions”. In: *Ecology* 84.5
348 (2003), pp. 1333–1339.
- 349 [22] Carl Mueller, Leonid Mytnik, and Jeremy Quastel. “Effect of noise on front propagation in
350 reaction-diffusion equations of KPP type”. In: *Invent. Math.* 184.2 (2011), pp. 405–453. ISSN:
351 0020-9910. DOI: 10.1007/s00222-010-0292-5.
- 352 [23] Florence Débarre and Thomas Lenormand. “Distance-limited dispersal promotes coexistence at
353 habitat boundaries: reconsidering the competitive exclusion principle”. In: *Ecology Letters* 14.3
354 (2011), pp. 260–266.
- 355 [24] Michael Lachmann and Eva Jablonka. “The inheritance of phenotypes: an adaptation to fluctu-
356 ating environments”. In: *Journal of theoretical biology* 181.1 (1996), pp. 1–9.
- 357 [25] Edo Kussell and Stanislas Leibler. “Phenotypic diversity, population growth, and information in
358 fluctuating environments”. In: *Science* 309.5743 (2005), pp. 2075–2078.
- 359 [26] Michael Baym et al. “Spatiotemporal microbial evolution on antibiotic landscapes”. In: *Science*
360 353.6304 (2016), pp. 1147–1151.
- 361 [27] Maxime Deforet et al. “Evolution at the edge of expanding populations”. In: *The American*
362 *Naturalist* 194.3 (2019), pp. 291–305.
- 363 [28] Ben Raymond. “Five rules for resistance management in the antibiotic apocalypse, a road map
364 for integrated microbial management”. In: *Evolutionary applications* 12.6 (2019), pp. 1079–1091.
- 365 [29] David V McLeod and Sylvain Gandon. “Understanding the evolution of multiple drug resistance
366 in structured populations”. In: *Elife* 10 (2021).
- 367 [30] Ramses Djidjou-Demasse, Benoît Moury, and Frédéric Fabre. “Mosaics often outperform pyra-
368 mids: insights from a model comparing strategies for the deployment of plant resistance genes
369 against viruses in agricultural landscapes”. In: *New Phytologist* 216.1 (2017), pp. 239–253.
- 370 [31] Loup Rimbaud et al. “Mosaics, mixtures, rotations or pyramiding: What is the optimal strategy
371 to deploy major gene resistance?” In: *Evolutionary Applications* 11.10 (2018), pp. 1791–1810.
- 372 [32] Loup Rimbaud et al. “Assessing the durability and efficiency of landscape-based strategies to
373 deploy plant resistance to pathogens”. In: *PLoS computational biology* 14.4 (2018), e1006067.
- 374 [33] Loup Rimbaud et al. “Models of plant resistance deployment”. In: *Annual Review of Phytopathol-*
375 *ogy* 59 (2021), pp. 125–152.
- 376 [34] H el ene Chabas et al. “Evolutionary emergence of infectious diseases in heterogeneous host pop-
377 ulations”. In: *PLoS biology* 16.9 (2018), e2006738.




Figure 1: Schematic presentation of the evolutionary epidemiology model and the spatial heterogeneity of the environment. Top figure: diagram of the compartmental model. S represents susceptible hosts, I_a (resp. I_b , I_m) represents hosts infected by the pathogen a resistant to drug A (resp. type b resistant to drug B , type m , resistant to both drugs A and B). In dashed we have represented mutations that typically happen at a much lower rate than transmissions. Bottom figure: Values of the intrinsic growth rates $x \mapsto r_a(x) = \beta_a(x) - \alpha$, $x \mapsto r_b(x) = \beta_b(x) - \alpha$, $x \mapsto r_m = \beta_m - \alpha$ as a function of the spatial variable $x \in \mathbb{R}$, where, for $x \in (0, L)$, $\beta_a(x) = 2r\mathbb{1}_{(0, \frac{L}{2})}(x)$ while $\beta_b(x) = 2r\mathbb{1}_{(\frac{L}{2}, L)}(x)$, and $\alpha = r$. The red (resp. green) area represents the locations $x \in \mathbb{R}$ treated with drug A (resp. B).




Figure 2: Propagation speed of single-resistance genotypes as a function of the period L and the mutation rate μ . We plot the speed c_a of a single specialist genotype (red line) and the speed c_{a+b} of a coalition of two specialists (orange lines) when $\mu_{ab} = \mu_{ba} = \mu$ (with $\mu_{am} = \mu_{bm} = 0$). The final values for c_a are extrapolated (from $L = 2000$ inclusive). The black arrows indicate the values of L_c for the different rates of mutation (see equation (4)). Parameters: $\sigma = 1$, $r = 1$, and the functions $\beta_a(x)$, $\beta_b(x)$, $r_a(x)$ and $r_b(x)$ are as in Figure 1.




Figure 3: Propagation speed when only one specialist type is present (c_a), both specialists are present (c_{a+b} with $\mu_{ab} = \mu_{ba} = \mu$) and when all the three resistant genotypes are present (c_{a+b+m} with $\mu_{ij} = \mu, \forall i, j \in \{a, b, m\}$). Top figure: speed of the epidemic in the *deterministic model* (1) against the period L for the coalition of specialists (orange line: c_{a+b} with $\mu_{ab} = \mu_{ba} = \mu$), the generalist alone (blue line: c_m) and the full model with both the specialists and the generalist (purple line: c_{a+b+m} with $\mu_{ij} = \mu, \forall i, j \in \{a, b, m\}$). Bottom figure: speed of the epidemic in the *stochastic model* with $N = 100$ and $\delta x = 0.1$. Parameters: $r = 1, r_m = \frac{1}{16}, \sigma = 1, \mu = 0.01, \beta_m = 1 + \frac{1}{16}$, and the functions $\beta_a(x), \beta_b(x), r_a(x)$ and $r_b(x)$ are as in Figure 1.




Figure 4: Effect of the mutation rate μ on the propagation speed of the epidemics when all three pathogen types are present (c_{a+b+m} with $\mu_{ij} = \mu, \forall i, j \in \{a, b, m\}$). Top figure: *deterministic model*. Bottom figure: *stochastic model* with $N = 100$ and $\delta x = 0.1$. Parameters: $\sigma = 1$, $r_m = \frac{1}{16}$, $r = 1$, $\beta_m = 1 + \frac{1}{16}$, and the functions $\beta_a(x)$, $\beta_b(x)$, $r_a(x)$ and $r_b(x)$ are as in Figure 1.





Figure 5: The five epidemic profiles. Composition of the population at the edge of the front (colors), and behind the front (hatches), as a function of r_m and L with $\mu_{ij} = \mu, \forall i, j \in \{a, b, m\}$. See also **Fig. S2, S3** and **S6** in the **Supplementary Information** for the description of these different epidemic profiles. Top figure: *deterministic model*. Bottom figure: *stochastic model* with $N = 100$ and $\delta x = 0.1$. Parameters: $\sigma = 1, \mu = 0.01, r = 1, \beta_m = 1 + r_m$, and the functions $\beta_a(x), \beta_b(x), r_a(x)$ and $r_b(x)$ are as in Figure 1.




Figure 6: Composition of the pathogen population at the front of the epidemic. Propagating epidemics for $r_m = 0.5$, $r = 1$, $\mu = 0.001$, $L = 10\beta_m = 1.5$, and the functions $\beta_a(x)$, $\beta_b(x)$, $r_a(x)$ and $r_b(x)$ are as in Figure 1. This corresponds to the epidemic type marked by **III** in **Fig. 5**.